SYS6020 for multiple sclerosis that has not responded to treatment
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with progressive MS or relapsing MS according to the 2024 McDonald criteria.
- Your MS has not responded well to at least one disease-modifying therapy taken for 6 months or more.
- You have had increased disability or relapses despite treatment, or new lesions on MRI.
- You have a positive cerebrospinal fluid test (oligoclonal bands) or elevated IgG index.
- You have typical MS lesions on brain or spinal cord MRI.
- Your disability score (EDSS) is between 3.0 and 7.0.
- Your organ function is adequate (blood counts, liver, kidney, heart, etc.).
- You are willing to use reliable contraception for at least 2 years after the infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.